Drug Type Macrophage therapy, Protein drug conjugate |
Synonyms MDC-735 |
Target |
Action inhibitors |
Mechanism Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ovarian Cancer | Phase 1 | Switzerland | 28 Dec 2021 | |
Bladder Cancer | Phase 1 | Switzerland | - | |
Glioblastoma | Phase 1 | Switzerland | - | |
Lung Cancer | Phase 1 | Switzerland | - | |
Uterine Neoplasms | Phase 1 | Switzerland | - | |
Breast Cancer | Preclinical | Switzerland | 28 Apr 2025 | |
Breast Cancer | Preclinical | Switzerland | 28 Apr 2025 | |
Head and neck cancer metastatic | Preclinical | Switzerland | 28 Apr 2025 | |
Head and neck cancer metastatic | Preclinical | Switzerland | 28 Apr 2025 | |
Gastrointestinal Neoplasms | Preclinical | Finland | 01 Mar 2025 |